Viveve Medical (NASDAQ: VIVE) and Agilent Technologies (NYSE:A) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.
Insider & Institutional Ownership
40.6% of Viveve Medical shares are owned by institutional investors. 35.1% of Viveve Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Viveve Medical and Agilent Technologies’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Viveve Medical||$7.14 million||18.36||-$20.11 million||($2.16)||-1.96|
|Agilent Technologies||$4.47 billion||5.13||$684.00 million||$0.59||120.49|
Agilent Technologies has higher revenue and earnings than Viveve Medical. Viveve Medical is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.
This table compares Viveve Medical and Agilent Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for Viveve Medical and Agilent Technologies, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Viveve Medical currently has a consensus target price of $10.00, suggesting a potential upside of 135.85%. Agilent Technologies has a consensus target price of $70.59, suggesting a potential downside of 0.70%. Given Viveve Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Viveve Medical is more favorable than Agilent Technologies.
Agilent Technologies pays an annual dividend of $0.60 per share and has a dividend yield of 0.8%. Viveve Medical does not pay a dividend. Agilent Technologies pays out 101.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viveve Medical has increased its dividend for 2 consecutive years.
Volatility & Risk
Viveve Medical has a beta of -0.79, indicating that its share price is 179% less volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.
Agilent Technologies beats Viveve Medical on 9 of the 16 factors compared between the two stocks.
Viveve Medical Company Profile
Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician’s office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.
Agilent Technologies Company Profile
Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.